Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Government Unveils Four-Chapter Outline for 2026 Honebuto
The Japanese government on June 25 unveiled the outline for its 2026 Basic Policy on Economic and Fiscal Management and Reform (honebuto), which will comprise four chapters covering macroeconomic management, growth strategy, long-term economic sustainability, and FY2027 budget planning. The…
To read the full story
Related Article
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- LDP Lawmakers Renew Calls to Reflect Inflation in Drug Prices
July 8, 2026
- Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
- LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
REGULATORY
- Japan Cabinet Approves Food Tax Cut Outline; 1% Rate for 2 Years
September 16, 2026
- MHLW to Track Prescription Shifts under OTC-Like Drug Charge
September 16, 2026
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…